Evidence map›Paper›PMID 41922612›Full record

ArticleScientific reports2026

Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk.

Takuya Masuda, Yasutaka Mochizuka, Yuzo Suzuki, Masato Kono, Sayomi Matsushima, Shinpei Kato, Kosuke Suzuki, Kazuki Tanaka, Keigo Koda, Toshihiro Masuda and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Takuya MasudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yasutaka MochizukaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yuzo SuzukiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. yuzosuzu@hama-med.ac.jp.
Masato KonoDepartment of Respiratory Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Sayomi MatsushimaDepartment of Respiratory Medicine, Iwata City Hospital, Hamamatsu, Japan.
Shinpei KatoDepartment of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Kosuke SuzukiDepartment of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
Kazuki TanakaDepartment of Respiratory Medicine, Fujieda City Hospital, Fujieda, Japan.
Keigo KodaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Shizuoka, Japan.
Toshihiro MasudaDepartment of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Miho KanaiDepartment Respiratory Medicine, Tenryu Hospital, National Hospital Organization, Hamamatsu, Japan.
Masaki IkedaDepartment Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan.
Mitsuru NiwaDepartment Respiratory Medicine, Hamamatsu Medical Center, Hamamatsu, Japan.
Yusuke KaidaDepartment of Respiratory Medicine, JA Shizuoka Kohseiren Enshu Hospital, Hamamatsu, Japan.
Hiroyuki MatsudaDepartment of Respiratory Medicine, Shizuoka Red Cross Hospital, Shizuoka, Japan.
Masanori HaradaDepartment of Respiratory Medicine, Iwata City Hospital, Hamamatsu, Japan.
Dai HashimotoDepartment of Respiratory Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Kazuhiro AsadaDepartment of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
Koshi YokomuraDepartment of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Mikio ToyoshimaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Shizuoka, Japan.
Yusuke InoueSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hideki YasuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hironao HozumiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Masato KarayamaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kazuki FuruhashiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Noriyuki EnomotoSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Tomoyuki FujisawaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Naoki InuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Funding

Japan Society for the Promotion of Science 22K08279
6 · The paper itself

Abstract

No prospective studies have investigated the relationship between nutritional status, tolerability to antifibrotic therapy, and mortality in patients with fibrotic interstitial lung diseases (ILDs). This prospective longitudinal study enrolled 290 consecutive patients with fibrotic ILDs who initiated antifibrotic therapy, including 164 with idiopathic pulmonary fibrosis (IPF) and 126 with non-IPF. Nutritional status was assessed using the Geriatric Nutritional Risk Index (GNRI). Overall, 106 patients (36.6%) were classified as having malnutrition-related risk (GNRI < 98) at baseline. The prevalence of malnutrition-related risk was comparable between patients with IPF and non-IPF, although it tended to be higher in the non-IPF group than in the IPF group. Patients with malnutrition-related risk showed higher cumulative incidence of antifibrotic therapy discontinuation. Importantly, in both IPF and non-IPF groups, the mortality risk was significantly higher in patients with malnutrition-related risk than in those without. Longitudinally, a lower GNRI at 1 year was associated with shorter survival. In multivariable analyses, baseline malnutrition-related risk was independently associated with increased risk of therapy discontinuation and mortality, even after adjusting for the ILD-gender-age-physiology index. These findings indicate that assessment of nutritional status helps predict antifibrotic therapy tolerability and mortality risk in patients with fibrotic ILD.

Indexed as

Antifibrotic AgentsGeriatric AssessmentIdiopathic Pulmonary FibrosisLung Diseases, InterstitialMalnutritionNutritional StatusNutrition AssessmentAgedAged, 80 and overFemaleHumansLongitudinal StudiesMaleProspective StudiesRisk FactorsAntifibrotic AgentsAntifibrotic therapyFibrotic interstitial lung diseaseGeriatric nutritional risk indexMalnutrition-related riskMortalityTolerability

Identifiers

PMID41922612
PMCPMC13181005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.